Development of novel antimicrobials with engineered endolysin LysECD7-SMAP to combat Gram-negative bacterial infections.
Daria V VasinaNataliia P AntonovaVladimir A GushchinAndrey V AleshkinMikhail V FursovAnastasiia D FursovaPetya G GanchevaIgor V GrigorievPavel GrinkevichAlexey V KondratevAlexey V KostarnoyAnastasiya M LendelValentine V MakarovMaria A NikiforovaAndrei A PochtovyiTatiana PrudnikovaTimofey A RemizovNatalia V ShevlyaginaAndrei E SiniavinNina S SmirnovaAlexander A TerechovArtem P TkachukEvgeny V UsachevAleksei M VorobevVictoria S YakimakhaSergey M YudinAnastasia A ZackharovaVladimir G ZhukhovitskyDenis Y LogunovAlexander L GintsburgPublished in: Journal of biomedical science (2024)
Our studies demonstrate the potential of LysECD7-SMAP therapeutics for the systemic or topical treatment of infectious diseases caused by susceptible Gram-negative bacterial species and are critical to proceed LysECD7-SMAP-based antimicrobials trials to advanced stages.